- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00657176
An Open-Label Phase-1 Study of OPB-31121 in Patients With Advanced Solid Tumors
April 17, 2008 updated by: Korea Otsuka Pharmaceutical Co., Ltd.
A Phase 1, Open-Label, Non-Randomized Study of OPB-31121 in Patients With Advanced Solid Tumors
This is an open-label, non-randomized, single-center, dose-escalation study in patients with advanced solid tumors.
Six dose levels (100, 200, 400, 600, 800, and 1000 mg/day) are planned for the study.
In this study, OPB-31121's potential for toxic effects will be evaluated in patients with advanced solid tumors to evaluate the recommended dose for use in subsequent studies.
The pharmacokinetics and antitumor effect of the compound will also be investigated.
Study Overview
Study Type
Interventional
Enrollment (Anticipated)
36
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Yung-Jue Bang, PhD
- Phone Number: 82-2-2072-2390
- Email: bangyj@snu.ac.kr
Study Contact Backup
- Name: Hanna Lee, Bachelor
- Phone Number: 82-2-2072-0603
- Email: life1025@naver.com
Study Locations
-
-
-
Seoul, Korea, Republic of, 110-744
- Recruiting
- Seoul National University Hospital
-
Contact:
- Hanna Lee, Bachelor
- Phone Number: +82-2-2072-0603
- Email: life1025@naver.com
-
Principal Investigator:
- Yung-Jue Bang, PhD
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
19 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria
- Histologically confirmed solid tumor refractory to standard therapy or for which there is no standard therapy
- Age: more than 19 years
- ECOG performance status: less than 2
- Life expectancy of longer than 3 months
Adequate vital organ function as follows:
Bone marrow function
- neutrophils: more than 1,500 per microliter
- platelets: more than 75,000 per microliter
- hemoglobin: more than 10.0g per deciliter
Hepatic function
- AST and ALT: less than 2.5 x institutional upper limit normal
- serum total bilirubin: less than 2.5 x institutional ULN
Renal function
- Serum creatinine: less than 1.5 x institutional ULN
- Capable of swallowing OPB-31121 tablets
- Ability to understand and willingness to sign written informed consent document for participation in the trial and for analysis of genotypes CYP2C9 and NAT2
- No chemotherapy, radiotherapy, surgery, or immunotherapy within 4 weeks prior to study entry and recovered from any prior toxicity
Exclusion criteria:
- Symptomatic CNS metastasis
- Uncontrolled concurrent illness, including active infection, heart failure, angina pectoris, and cardiac arrhythmia
- Psychiatric illness that would limit compliance with study requirements
- Pregnant or breast-feeding women and women of childbearing potential who cannot or will not use effective contraceptive measures
- Administration of another investigational agent within 6 months prior to study entry
- Use of CYP3A4 and CYP2C9 inducers, inhibitors, or substrates, and CYP2B6, CYP2C8 and CYP2D6 substrates
Hyperlipidemia:
Total cholesterol:more than 300 milligram per deciliter or Triglycerides:
more than 2.5 x institutional ULN
- Abnormal thyroid function: Hypothyroidism or hyperthyroidism of grade 2 or higher (graded according to the NCI-CTCAE)
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Maximum tolerated dose
Time Frame: Cycle 1
|
Cycle 1
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Pharmacokinetics
Time Frame: Cycle 1
|
Cycle 1
|
Safety and dose-limiting toxicity
Time Frame: Duration of Study
|
Duration of Study
|
Antitumor effect
Time Frame: Duration of study
|
Duration of study
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Yung-Jue Bang, PhD, Division of Hematology and Medical Oncology, Seoul National University Hospital
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
March 1, 2008
Primary Completion (Anticipated)
March 1, 2009
Study Completion (Anticipated)
June 1, 2009
Study Registration Dates
First Submitted
April 9, 2008
First Submitted That Met QC Criteria
April 11, 2008
First Posted (Estimate)
April 14, 2008
Study Record Updates
Last Update Posted (Estimate)
April 18, 2008
Last Update Submitted That Met QC Criteria
April 17, 2008
Last Verified
April 1, 2008
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 252-KOA-0701
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Solid Tumor
-
Memorial Sloan Kettering Cancer CenterRecruitingSolid Tumor | Solid Tumor, Adult | Solid Tumor, Unspecified, AdultUnited States
-
Memorial Sloan Kettering Cancer CenterLincoln Medical and Mental Health CenterRecruitingSolid Tumor | Solid Tumor, Adult | Solid Tumor, Unspecified, AdultUnited States, Puerto Rico
-
Memorial Sloan Kettering Cancer CenterLincoln Medical and Mental Health CenterRecruitingSolid Tumor | Solid Tumor, Adult | Solid Tumor, Unspecified, AdultUnited States, Puerto Rico
-
Aadi Bioscience, Inc.RecruitingAdvanced Solid Tumor | Tumor | Tumor, SolidUnited States
-
RemeGen Co., Ltd.CompletedMetastatic Solid Tumor | Locally Advanced Solid Tumor | Unresectable Solid TumorAustralia
-
Sorrento Therapeutics, Inc.WithdrawnSolid Tumor | Relapsed Solid Tumor | Refractory Tumor
-
Impact Therapeutics, Inc.RecruitingSolid Tumor | Advanced Solid TumorChina, Taiwan, United States, Australia
-
Partner Therapeutics, Inc.WithdrawnSolid Tumor | Solid Tumor, AdultUnited States
-
Shenzhen Ionova Life Sciences Co., Ltd.Merck Sharp & Dohme LLCRecruitingCancer | Solid Tumor, Adult | Solid Carcinoma | Solid Tumor, Unspecified, Adult | Cancer Metastatic | Tumor, SolidUnited States
-
BeiGeneRecruitingSolid Tumor | Advanced Solid TumorUnited States, New Zealand, Australia, China
Clinical Trials on OPB-31121
-
Otsuka Pharmaceutical Co., Ltd.CompletedHepatocellular CarcinomaJapan
-
Otsuka Beijing Research InstituteOtsuka Pharmaceutical Co., Ltd.UnknownNon-Hodgkin's Lymphoma(NHL) | Multiple Myeloma(MM)Hong Kong
-
M.D. Anderson Cancer CenterOtsuka Pharmaceutical Development & Commercialization, Inc.Completed
-
M.D. Anderson Cancer CenterOtsuka Pharmaceutical Co., Ltd.Terminated
-
Hospital Universitario 12 de OctubreApices Soluciones S.L.; Otsuka Pharmaceutical Co., Ltd.; Vivia BiotechCompletedAcute Myeloid LeukemiaSpain
-
Otsuka Pharmaceutical Co., Ltd.CompletedAcute Myeloid Leukemia | Multiple Myeloma | Non-Hodgkin Lymphoma | Chronic Myeloid Leukemia | Acute Lymphoid LeukemiaJapan
-
National University Hospital, SingaporeOtsuka Pharmaceutical Co., Ltd.; Shin Nippon Biomedical Laboratories, Ltd.TerminatedNasopharyngeal CarcinomaSingapore
-
Otsuka Pharmaceutical Development & Commercialization...Completed
-
Otsuka Beijing Research InstituteCompletedMalignant Solid TumourSingapore
-
Korea Otsuka Pharmaceutical Co., Ltd.Otsuka Pharmaceutical Co., Ltd.CompletedSolid TumorKorea, Republic of